Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK1702934A is a selective TRPC3 agonist. It modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3.
Description | GSK1702934A is a selective TRPC3 agonist. It modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3. |
In vitro | GSK1702934A induces transient, non-selective conductance and extends the duration of action potentials in TRPC3-overexpressing myocytes, an effect not observed in wild-type myocytes[2]. Furthermore, it effectively initiates TRPC3/6-currents in HEK293 cells expressing recombinant human TRPC3/6, with half-maximal effective concentrations (EC50) of 0.08 mM for TRPC3 and 0.44 mM for TRPC6, respectively[1]. Additionally, GSK1702934A significantly enhances NCX currents in TRPC3-overexpressing myocytes[2]. |
Molecular Weight | 395.52 |
Formula | C22H25N3O2S |
CAS No. | 924377-85-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK1702934A 924377-85-5 Others GSK-1702934A inhibitor inhibit